Daniel R. Chevallard - Net Worth and Insider Trading
Daniel R. Chevallard Net Worth
The estimated net worth of Daniel R. Chevallard is at least $140,660 dollars as of 2024-12-01. Daniel R. Chevallard is the CFO of LENZ Therapeutics Inc and owns about 3,188 shares of LENZ Therapeutics Inc (LENZ) stock worth over $113,493. Daniel R. Chevallard is the CFO and COO of Viracta Therapeutics Inc and owns about 102,306 shares of Viracta Therapeutics Inc (VIRX) stock worth over $14,630. Daniel R. Chevallard is also the CFO of Regulus Therapeutics Inc and owns about 7,787 shares of Regulus Therapeutics Inc (RGLS) stock worth over $12,537. Details can be seen in Daniel R. Chevallard's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Daniel R. Chevallard has not made any transactions after 2024-05-14 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Daniel R. Chevallard
Daniel R. Chevallard Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Daniel R. Chevallard owns 2 companies in total, including Regulus Therapeutics Inc (RGLS) , and Viracta Therapeutics Inc (VIRX) .
Click here to see the complete history of Daniel R. Chevallard’s form 4 insider trades.
Insider Ownership Summary of Daniel R. Chevallard
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| RGLS | Regulus Therapeutics Inc | 2019-07-01 | Chief Financial Officer |
| VIRX | Viracta Therapeutics Inc | 2024-02-27 | Chief Executive Officer |
Daniel R. Chevallard Latest Holdings Summary
Daniel R. Chevallard currently owns a total of 3 stocks. Among these stocks, Daniel R. Chevallard owns 3,188 shares of LENZ Therapeutics Inc (LENZ) as of May 14, 2024, with a value of $113,493 and a weighting of 80.69%. Daniel R. Chevallard owns 102,306 shares of Viracta Therapeutics Inc (VIRX) as of February 27, 2024, with a value of $14,630 and a weighting of 10.4%. Daniel R. Chevallard also owns 7,787 shares of Regulus Therapeutics Inc (RGLS) as of July 1, 2019, with a value of $12,537 and a weighting of 8.91%.
Latest Holdings of Daniel R. Chevallard
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| LENZ | LENZ Therapeutics Inc | 2024-05-14 | 3,188 | 35.60 | 113,493 |
| VIRX | Viracta Therapeutics Inc | 2024-02-27 | 102,306 | 0.14 | 14,630 |
| RGLS | Regulus Therapeutics Inc | 2019-07-01 | 7,787 | 1.61 | 12,537 |
Holding Weightings of Daniel R. Chevallard
Daniel R. Chevallard Form 4 Trading Tracker
According to the SEC Form 4 filings, Daniel R. Chevallard has made a total of 1 transactions in LENZ Therapeutics Inc (LENZ) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in LENZ Therapeutics Inc is the acquisition of 3,188 shares on May 14, 2024, which cost Daniel R. Chevallard around $49,988.
According to the SEC Form 4 filings, Daniel R. Chevallard has made a total of 10 transactions in Viracta Therapeutics Inc (VIRX) over the past 5 years, including 0 buys and 10 sells. The most-recent trade in Viracta Therapeutics Inc is the sale of 3,405 shares on February 27, 2024, which brought Daniel R. Chevallard around $2,486.
According to the SEC Form 4 filings, Daniel R. Chevallard has made a total of 0 transactions in Regulus Therapeutics Inc (RGLS) over the past 5 years. The most-recent trade in Regulus Therapeutics Inc is the sale of 267 shares on July 1, 2019, which brought Daniel R. Chevallard around $3,496.
Insider Trading History of Daniel R. Chevallard
- 1
Daniel R. Chevallard Trading Performance
GuruFocus tracks the stock performance after each of Daniel R. Chevallard's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Daniel R. Chevallard is 26.55%. GuruFocus also compares Daniel R. Chevallard's trading performance to market benchmark return within the same time period. The performance of stocks bought by Daniel R. Chevallard within 3 months outperforms 2 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Daniel R. Chevallard's insider trading performs compared to the benchmark.
Performance of Daniel R. Chevallard
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 2.22 | | | | | |
| Relative Return to S&P 500(%) | 1.15 | | | | | |
Daniel R. Chevallard Ownership Network
Daniel R. Chevallard Owned Company Details
What does Regulus Therapeutics Inc do?
Who are the key executives at Regulus Therapeutics Inc?
Daniel R. Chevallard is the Chief Financial Officer of Regulus Therapeutics Inc. Other key executives at Regulus Therapeutics Inc include Chief Financial Officer Crispina Calsada , Sr. VP & General Counsel Christopher Ray Aker , and Chief Operating Officer Joseph P Hagan .
Regulus Therapeutics Inc (RGLS) Insider Trades Summary
Over the past 18 months, Daniel R. Chevallard made no insider transaction in Regulus Therapeutics Inc (RGLS). Other recent insider transactions involving Regulus Therapeutics Inc (RGLS) include a net sale of 14,580 shares made by Joseph P Hagan , a net sale of 5,468 shares made by Christopher Ray Aker , and a net sale of 5,468 shares made by Crispina Calsada .
In summary, during the past 3 months, insiders sold 0 shares of Regulus Therapeutics Inc (RGLS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 25,516 shares of Regulus Therapeutics Inc (RGLS) were sold and 4,000 shares were bought by its insiders, resulting in a net sale of 21,516 shares.
Regulus Therapeutics Inc (RGLS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Regulus Therapeutics Inc Insider Transactions
Daniel R. Chevallard Mailing Address
Above is the net worth, insider trading, and ownership report for Daniel R. Chevallard. You might contact Daniel R. Chevallard via mailing address: C/o Regulus Therapeutics Inc., 10614 Science Center Drive, San Diego Ca 92121.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
